21 min listen
Should Investors Temper Their Enthusiasm for CAR-T Therapies
FromThe Bio Report
ratings:
Length:
24 minutes
Released:
Feb 5, 2015
Format:
Podcast episode
Description
CAR-T cell immunotherapies seek to harness the body’s immune system to fight tumor cells. The promise of this new class of therapies has ignited investor’s imaginations, but a new report from EP Vantage argues that the enthusiasm that has driven valuations of CAR-T companies should be tempered by an eye towards the risks. We spoke to Jacob Plieth, report author and senior reporter for EP Vantage, about the promise of these therapies, what we know about their safety and efficacy, and why the muddy intellectual property landscape is a concern.
Released:
Feb 5, 2015
Format:
Podcast episode
Titles in the series (100)
The Forces Bringing Disruptive Change to Healthcare: Scientific breakthroughs, innovations in technology, and the changing use of data are among the forces that are driving disruptive changes to healthcare. A new report from the IMS Institute for Healthcare Informatics highlights a number of these deve... by The Bio Report